- Home
- YI vs EQ Comparison
YI vs EQ Comparison
Compare YI & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- EQ
- Stock Information
- Founded
- YI 2010
- EQ 2017
- Country
- YI China
- EQ United States
- Employees
- YI N/A
- EQ N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- YI Consumer Staples
- EQ Health Care
- Exchange
- YI Nasdaq
- EQ Nasdaq
- Market Cap
- YI 60.7M
- EQ 67.9M
- IPO Year
- YI N/A
- EQ 2018
- Fundamental
- Price
- YI $5.42
- EQ $1.50
- Analyst Decision
- YI
- EQ Hold
- Analyst Count
- YI 0
- EQ 2
- Target Price
- YI N/A
- EQ $1.00
- AVG Volume (30 Days)
- YI 22.3K
- EQ 2.5M
- Earning Date
- YI 09-17-2025
- EQ 11-12-2025
- Dividend Yield
- YI N/A
- EQ N/A
- EPS Growth
- YI N/A
- EQ N/A
- EPS
- YI N/A
- EQ N/A
- Revenue
- YI $1,979,883,442.00
- EQ $16,553,000.00
- Revenue This Year
- YI N/A
- EQ N/A
- Revenue Next Year
- YI N/A
- EQ N/A
- P/E Ratio
- YI N/A
- EQ N/A
- Revenue Growth
- YI N/A
- EQ N/A
- 52 Week Low
- YI $4.15
- EQ $0.27
- 52 Week High
- YI $11.90
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- YI 32.37
- EQ 48.79
- Support Level
- YI $5.51
- EQ $1.78
- Resistance Level
- YI $6.37
- EQ $2.02
- Average True Range (ATR)
- YI 0.54
- EQ 0.26
- MACD
- YI -0.03
- EQ -0.09
- Stochastic Oscillator
- YI 4.42
- EQ 1.73
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.